Dashboard
Manage Tickers

MRSN


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

citigroup-maintains-buy-on-mersana-therapeutics-lowers-price-target-to-5
Citigroup Maintains Buy on Mersana Therape...
08/27/2024 14:40:08

Citigroup analyst Ashiq Mubarack maintains Mersana Therapeutics (NASDAQ:MRSN) with a Buy and lowers the price target from $6...

baird-maintains-neutral-on-mersana-therapeutics-lowers-price-target-to-3
Baird Maintains Neutral on Mersana Therape...
08/14/2024 11:41:18

Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Neutral and lowers the price target from $4 t...

mersana-therapeutics-continues-to-expect-capital-resources-will-support-current-operating-plan-commitments-into-2026
Mersana Therapeutics Continues To Expect C...
08/13/2024 11:03:49

mersana-therapeutics-q2-2024-gaap-eps-020-misses-017-estimate-sales-2293m-miss-8722m-estimate
Mersana Therapeutics Q2 2024 GAAP EPS $(0....
08/13/2024 11:03:13

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate o...

mersana-therapeutics-continues-to-expect-capital-resources-will-support-current-operating-plan-commitments-into-2026
Mersana Therapeutics Continues To Expect C...
05/09/2024 11:11:55

mersana-therapeutics-q1-2024-gaap-eps-016-beats-019-estimate-sales-9245m-beat-8500m-estimate
Mersana Therapeutics Q1 2024 GAAP EPS $(0....
05/09/2024 11:11:07

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of ...

why-teledyne-technologies-shares-are-trading-lower-by-9-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Teledyne Technologies Shares Are Tradi...
04/24/2024 17:57:43

the-analyst-verdict-mersana-therapeutics-in-the-eyes-of-5-experts
The Analyst Verdict: Mersana Therapeutics ...
03/19/2024 13:00:37

jp-morgan-upgrades-mersana-therapeutics-to-neutral-announces-5-price-target
JP Morgan Upgrades Mersana Therapeutics to...
03/19/2024 09:50:17

JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics (NASDAQ:MRSN) from Underweight to Neutral and announces $5 price...

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
03/15/2024 21:33:52

why-butterfly-network-shares-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Butterfly Network Shares Are Trading L...
02/29/2024 19:00:01

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...

hormel-foods-reports-upbeat-earnings-joins-pure-storage-okta-papa-johns-international-and-other-big-stocks-moving-higher-on-thursday
Hormel Foods Reports Upbeat Earnings, Join...
02/29/2024 16:30:35

U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday.

expert-outlook-mersana-therapeutics-through-the-eyes-of-5-analysts
Expert Outlook: Mersana Therapeutics Throu...
02/29/2024 16:00:51

wedbush-upgrades-mersana-therapeutics-to-outperform-raises-price-target-to-7
Wedbush Upgrades Mersana Therapeutics to O...
02/29/2024 15:51:48

Wedbush analyst David Nierengarten upgrades Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Outperform and raises the pri...

truist-securities-upgrades-mersana-therapeutics-to-buy-maintains-price-target-to-9
Truist Securities Upgrades Mersana Therape...
02/29/2024 14:03:40

Truist Securities analyst Asthika Goonewardene upgrades Mersana Therapeutics (NASDAQ:MRSN) from Hold to Buy and maintains th...

baird-maintains-neutral-on-mersana-therapeutics-raises-price-target-to-5
Baird Maintains Neutral on Mersana Therape...
02/29/2024 12:17:32

Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Neutral and raises the price target from $1 t...

guggenheim-upgrades-mersana-therapeutics-to-buy-announces-7-price-target
Guggenheim Upgrades Mersana Therapeutics t...
02/29/2024 10:57:32

Guggenheim analyst Michael Schmidt upgrades Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Buy and announces $7 price ta...

mersana-therapeutics-continues-to-expect-capital-resources-will-support-current-operating-plan-commitments-into-2026
Mersana Therapeutics Continues To Expect C...
02/28/2024 12:09:34

mersana-therapeutics-q4-eps-016-inline-sales-1070m-miss-1477m-estimate
Mersana Therapeutics Q4 EPS $(0.16), Inlin...
02/28/2024 12:02:25

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. Thi...

earnings-scheduled-for-february-28-2024
Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION